Cover Image
市場調查報告書

全球生技仿製藥市場預測

Global Biosimilar Market Outlook 2022

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 296320
出版日期 內容資訊 英文 135 Pages
訂單完成後即時交付
價格
Back to Top
全球生技仿製藥市場預測 Global Biosimilar Market Outlook 2022
出版日期: 2016年09月01日 內容資訊: 英文 135 Pages
簡介

全球生技仿製藥市場,預計2016年∼2022年以2位數高成長。

本報告提供全球生技仿製藥市場相關調查分析,以現在、未來市場方案為焦點,提供主要推動因素與課題,最新的趨勢與發展,各種成長機會等相關的系統性資訊。

第1章 分析師的見解

第2章 調查手法

第3章 全球生技仿製藥市場預測

第4章 市場動態

  • 推動因素
  • 課題
  • 機會

第5章 市場區隔:各類型產品

  • 促血紅細胞生長素 (EPO)
  • 人體生長荷爾蒙 (HGH)
  • 顆粒細胞增生因子 (G-CSF)
  • 單株抗體 (mAb)
  • 胰島素
  • 干擾素 (IFN)
  • 其他

第6章 市場區隔:各地區

  • 歐洲
  • 亞太地區
  • 北美
  • 其他

第7章 市場區隔:各用途

  • 腫瘤學
  • 血液疾病
  • 其他

第8章 市場趨勢與發展

  • 組合式的生技仿製藥廠房的發展
  • 腫瘤學的生技仿製藥

第9章 M&A

第10章 波特的五力分析

第11章 競爭情形

  • 主要企業的市場佔有率
  • 企業簡介
    • Biocad
    • Celltrion Inc.
    • Dong-A Socio Group
    • Pfizer Inc.
    • Intas Pharmaceuticals Ltd.
    • Sandoz International GmbH
    • Stada Arzneimittel AG
    • Teva Pharmaceutical Industries Ltd.
    • Amgen Inc.
    • Biocon

第12章 未來預測

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

A biosimilar is a biologic product that is similar to a regulatory body approved reference product, and has no clinically meaningful differences in terms of safety and effectiveness from that reference product. Only minor differences in clinically inactive components are allowable in biosimilar products. The global biosimilars market is expected to witness a steep growth owing to the patent expiry of blockbuster biologic drugs. The ability of biosimilars to reduce healthcare costs is another driving factor for this industry. Furthermore, the recent approval of three biosimilars in the US market is providing an impetus to more biopharmaceutical companies to enter this field.

As per RNCOS report “Global Biosimilar Market Outlook 2022”, the global biosimilars market is anticipated to witness a high double digit growth during 2016-2022. This report provides a detailed analysis of the current and future market scenario of the global biosimilars market. The report provides insight about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global biosimilars market.

The global biosimilars market has been segmented on the basis of type of product. The major types of biosimilars present in the market include monoclonal antibodies, erythropoietin, insulin, G-CSF, HGH, and interferon amongst others. The report also highlights the various biosimilar drugs available in the market, and the biosimilars currently in various phases of clinical trials.

Furthermore, the global biosimilars market has also been segmented on the basis of their applications. According to the report, oncology is expected to account for the largest share in 2016 due to presence of large number of biosimilars for this indication. Based on geography, the report divides the market into Europe, Asia-Pacific, North America and Rest of the World. In 2016, Europe is expected to account for the largest share. Moreover, the report also lists down various mergers and acquisitions taking place in the global biosimilars industry.

The last section of the report discusses about the prominent players in global biosimilars market. Market share analysis of these players is also provided in the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios and clinical pipelines. The recent development of every player has also been presented in the report. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the global biosimilars market.

Table of Contents

1. Analyst View

2. Research Methodology

3. Global Biosimilars Market Outlook 2022

4. Market Dynamics

  • 4.1. Drivers
    • 4.1.1. Growing Geriatric Population
    • 4.1.2. Entry of Biosimilars in the US Market
    • 4.1.3. Ability to Curb Healthcare Cost
    • 4.1.4. Rising Incidences of Chronic Diseases
    • 4.1.5. Government Initiatives
  • 4.2. Challenges
    • 4.2.1. Regulatory Issues
    • 4.2.2. Greater Litigation Risk
    • 4.2.3. Lack of Standardized Manufacturing Process
  • 4.3. Opportunities
    • 4.3.1. Emerging Markets - Area of Opportunities for Biosimilars
    • 4.3.2. Patent Expiry of Blockbuster Biologics

5. Market Segmentation by Product Type

  • 5.1. Erythropoietin (EPO)
  • 5.2. Human Growth Hormone (HGH)
  • 5.3. Granulocyte- Colony Stimulating Factor (G-CSF)
  • 5.4. Monoclonal Antibody (mAb)
  • 5.5. Insulin
  • 5.6. Interferon (IFN)
  • 5.7. Others

6. Market Segmentation by Geography

  • 6.1. Europe
    • 6.1.1. Germany
    • 6.1.2. France
    • 6.1.3. Italy
    • 6.1.4. Spain
    • 6.1.5. UK
  • 6.2. Asia-Pacific
    • 6.2.1. India
    • 6.2.2. China
    • 6.2.3. Japan
  • 6.3. North America
    • 6.3.1. US
    • 6.3.2. Canada
  • 6.4. Rest of the World

7. Market Segmentation by Applications

  • 7.1. Oncology
  • 7.2. Blood Disorders
  • 7.3. Others

8. Market Trends and Developments

  • 8.1. Development of Modular Biosimilar Plants
  • 8.2. Biosimilars in Oncology

    9. Mergers and Acquisitions

    10. Porter's Five Forces Analysis

11. Competitive Landscape

  • 11.1. Market Share of Major Players
  • 11.2. Company Profiles
    • 11.2.1. Biocad
    • 11.2.2. Celltrion Inc.
    • 11.2.3. Dong-A Socio Group
    • 11.2.4. Pfizer Inc.
    • 11.2.5. Intas Pharmaceuticals Ltd.
    • 11.2.6. Sandoz International GmbH - A Novartis Company
    • 11.2.7. Stada Arzneimittel AG
    • 11.2.8. Teva Pharmaceutical Industries Ltd.
    • 11.2.9. Amgen Inc.
    • 11.2.10. Biocon

12. Future Outlook

List of Figures:

  • Figure 3-1: Global - Biosimilars Market (Million US$), 2016 & 2022
  • Figure 4-1: Global - Population above 60 Years (Billion), 2013 & 2050
  • Figure 4-2: World's Best Selling Biologics and their Patent Expiry in the US & EU
  • Figure 5-1: Global - Biosimilars Market by Product Type (%), 2016
  • Figure 5-2: Global - Erythropoietin Biosimilars Market (Million US$), 2016 & 2022
  • Figure 5-3: Global - HGH Biosimilars Market (Million US$), 2016 & 2022
  • Figure 5-4: Global - G-CSF Biosimilars Market (Million US$), 2016 & 2022
  • Figure 5-5: Global - mAb Biosimilars Market (Million US$), 2016 & 2022
  • Figure 5-6: Global - Insulin Biosimilars Market (Million US$), 2016 & 2022
  • Figure 5-7: Global - Interferon Biosimilars Market (Million US$), 2016 & 2022
  • Figure 5-8: Global - Other Biosimilars Market (Million US$), 2016 & 2022
  • Figure 6-1: Global - Biosimilars Market by Key Geographies (%), 2016
  • Figure 6-2: Europe - Biosimilars Market (Million US$), 2016 & 2022
  • Figure 6-3: Europe - Biosimilars Market by Country (%), 2016
  • Figure 6-4: Germany - Biosimilars Market (Million US$), 2016 & 2022
  • Figure 6-5: France - Biosimilars Market (Million US$), 2016 & 2022
  • Figure 6-6: Italy - Biosimilars Market (Million US$), 2016 & 2022
  • Figure 6-7: Spain - Biosimilars Market (Million US$), 2016 & 2022
  • Figure 6-8: UK - Biosimilars Market (Million US$), 2016 & 2022
  • Figure 6-9: Asia Pacific - Biosimilars Market (Million US$), 2016 & 2022
  • Figure 6-10: Asia-Pacific - Biosimilars Market by Country (%), 2016
  • Figure 6-11: India - Biosimilars Market (Million US$), 2016 & 2022
  • Figure 6-12: China - Biosimilars Market (Million US$), 2016 & 2022
  • Figure 6-13: Japan - Biosimilars Market (Million US$), 2016 & 2022
  • Figure 6-14: North America - Biosimilars Market (Million US$), 2016 & 2022
  • Figure 6-15: North America - Biosimilars Market by Country (%), 2016
  • Figure 6-16: US - Biosimilars Market (Million US$), 2016 & 2022
  • Figure 6-17: Canada - Biosimilars Market (Million US$), 2016 & 2022
  • Figure 6-18: Rest of the World - Biosimilars Market (Million US$), 2016 & 2022
  • Figure 7-1: Global - Biosimilars Market by Applications (%), 2016
  • Figure 7-2: Global - Number of New Cancer Cases (Million), 2015 & 2025
  • Figure 7-3: Oncology - Biosimilars Market (Million US$), 2016 & 2022
  • Figure 7-4: Blood Disorders - Biosimilars Market (Million US$), 2016 & 2022
  • Figure 7-5: Other Diseases - Biosimilars Market (Million US$), 2016 & 2022
  • Figure 11-1: Market Share of Major Players in the Biosimilar Industry, 2015

List of Tables:

  • Table 5-1: Global - Biosimilar EPOs Approved for Marketing
  • Table 5-2: Global - Biosimilar EPOs in Pipeline
  • Table 5-3: Global - Biosimilar HGH Approved for Marketing
  • Table 5-4: Global - Biosimilar HGH in Pipeline
  • Table 5-5: Global - Biosimilar G-CSF Approved for Marketing
  • Table 5-6: Global - Biosimilar G-CSF in Pipeline
  • Table 5-7: Global - Biosimilar mAbs Approved for Marketing
  • Table 5-8: Global - Biosimilar mAbs in Pipeline
  • Table 5-9: Global - Biosimilar Insulin Approved for Marketing
  • Table 5-10: Global - Biosimilar Insulin in Pipeline
  • Table 5-11: Global - Biosimilar Interferons Approved for Marketing
  • Table 5-12: Global - Biosimilar Interferons in Pipeline
  • Table 9-1: Global - Major M&A in the Biosimilar Industry (2014-2016)
  • Table 11-1: Biocad - Major Biosimilars Approved for Marketing
  • Table 11-2: Biocad - Major Biosimilars in Pipeline
  • Table 11-3: Celltrion Inc. - Revenue (Million US$), 2013, 2014 & 2015
  • Table 11-4: Celltrion Inc. - Major Biosimilars Approved for Marketing
  • Table 11-5: Celltrion Inc. - Major Biosimilars in Pipeline
  • Table 11-6: Dong-A Socio Group - Revenue (Million US$), 2013, 2014 & 2015
  • Table 11-7: Dong-A Socio Group - Major Biosimilars in Pipeline
  • Table 11-8: Pfizer Inc. - Revenue (Million US$), 2013, 2014 & 2015
  • Table 11-9: Pfizer Inc. - Major Biosimilars Approved for Marketing
  • Table 11-10: Pfizer Inc. - Major Biosimilars in Pipeline
  • Table 11-11: Intas Pharmaceutical Ltd. - Revenue (Million US$), FY2013, FY2014 & FY2015
  • Table 11-12: Intas Pharmaceuticals Ltd. - Major Biosimilars Approved for Marketing
  • Table 11-13: Intas Pharmaceuticals Ltd. - Major Biosimilars in Pipeline
  • Table 11-14: Sandoz International GmbH - Revenue (Million US$), 2013, 2014 & 2015
  • Table 11-15: Sandoz International GmbH - Major Biosimilars Approved for Marketing
  • Table 11-16: Sandoz International GmbH - Major Biosimilars in Pipeline
  • Table 11-17: Stada Arzneimittel AG - Group Sales (Million US$), 2013, 2014 & 2015
  • Table 11-18: Stada Arzneimittel AG - Major Biosimilars Approved for Marketing
  • Table 11-19: Stada Arzneimittel AG - Major Biosimilars in Pipeline
  • Table 11-20: Teva Pharmaceutical Industries Ltd. - Net Sales (Million US$), 2013, 2014 & 2015
  • Table 11-21: Teva Pharmaceutical Industries Ltd. - Major Biosimilars Approved for Marketing
  • Table 11-22: Amgen Inc. - Total Company Revenue (Million US$), 2013, 2014 & 2015
  • Table 11-23: Amgen Inc. - Major Biosimilars in Pipeline
  • Table 11-24: Biocon - Revenue (Million US$), FY2014, FY2015 & FY2016
  • Table 11-25: Biocon - Major Biosimilars Approved for Marketing
  • Table 11-26: Biocon - Major Biosimilars in Pipeline
Back to Top